Breast Cancers Today
Dr. Rugo discusses SERENA-6, which showed ctDNA-guided camizestrant extends PFS in HR+/HER2- metastatic breast cancer.
A new review explores ILC’s unique radiosensitivity and how it could reshape breast cancer radiation strategies.
Genomic profiling reveals unique mutations in breast cancer in adults 65+, supporting age-specific treatment strategies.
Breastfeeding after breast cancer is safe for young BRCA carriers, new global data show—no impact on recurrence or ...
Drs Juneja, Graff, and Lustberg explore the most pressing topics in breast cancer, such as ADCs and post-CDK4/6 sequencing.
Radiation may benefit invasive lobular carcinoma, but more data is needed to guide histology-specific treatment strategies.
ADCs, ctDNA, and endocrine therapy advances headlined ASCO 2025 breast cancer updates across HER2+, HR+, and TNBC.
Triplet therapy showed promising efficacy in advanced TNBC in the ATRACTIB trial, with a 63% response rate.
Dr. Iyengar explains how metabolic health impacts cancer risk, treatment response, and outcomes across multiple tumor types.
Dr. Gradishar reviews PARP data, new combos, and tools to better select breast cancer patients for targeted treatment.
Dr Neil Iyengar joins Winship to lead breast oncology and survivorship, with a focus on metabolic health and cancer research.
HER2DX predicts outcomes in early HER2+ breast cancer, adding prognostic value beyond standard clinical-pathologic factors.
Dr. Sara Tolaney explores how DESTINY-Breast09 may reshape first-line treatment in HER2+ metastatic breast cancer.
Dr. Mark Robson discusses PARP inhibitors in TNBC, including mechanisms, combos, biomarkers, and treatment sequencing.
ChatGPT shows limited accuracy and consistency in breast cancer care, highlighting the need for expert clinical judgment.
Dr. Maryam Lustberg discusses real-world T-DXd use, biomarkers, and resistance in metastatic breast cancer care.
AI-enhanced HER2 scoring improves accuracy and may expand patient access to HER2-targeted therapies in breast cancer care.
Dr. Kelly McCann reviews sequencing and emerging therapies in HR-positive, HER2-negative metastatic breast cancer.
Dr. Kelly McCann of UCLA details HER2-positive breast cancer sequencing and toxicity management.
Dr. Kelly McCann discusses evolving treatment sequencing strategies in metastatic triple-negative breast cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.